# Pizarra — PT-pseudo_dcd61cf9b443 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd61cf9b443
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.215 ng/mL²
  - PSA velocity: 1.64 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 38.54 mL
  - Months since last PSA: 2
  - DRE findings: Suspicious (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86351734 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease
  - Problem list / PMHx: COPD, Chronic kidney disease
  - Current medication: ciprofloxacine
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.

Vitals: weight 63 kg, height 170 cm, BMI 21.8, BP 111/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2012).

Chief complaint: Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile.

History: Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012.

Physical examination: DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension.

Patient info: retired primary school teacher; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 33 units / week (heavy); exercise Cycling 2x/week, ~20 km; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult; Gastroenterology — surveillance colonoscopy.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.22   (95% CI 0.06-0.85)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.0 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=8.3, age=66.0, psad=0.215, dre_ord=2.0, vol=38.54, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5.0, PSA=8.3, Age=66, PSA Density=0.215, DRE=2.0, Volume=38.54 mL, N_PMHx=2.0) and failed to incorporate the crucial context of the prior positive biopsy status and the specific PSA velocity (1.64 ng/mL/yr).
The prior could not weigh the clinical significance of the rising PSA (from 7.9 to 8.3 ng/mL) in the context of a prior diagnosis, nor could it weigh the specific implications of the PI-RADS 5 score combined with the prior positive biopsy.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.43 +/- 0.22), meaning the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. The suggestion could be wrong because the prior failed to account for the guideline criterion that states the decision must be driven by retrieved documents, which it ignored. Specifically, a low PI-RADS score (if the prior was misread) against a rising PSA, or a prior positive biopsy, could drastically change the risk profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive biopsy
laboratory panel - full panel
family-history anamnesis - for any genetic predisposition

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically assessing whether the prior grade is documented, if the lesion changed against a previous MRI, and if a surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Erasmus MC | 10 January 2025
The gland spans 38.54 mL. A discrete focus measuring roughly 18 x 14 x 12 mm occupies the left peripheral zone, spanning base to mid-gland. T2 sequences highlight pronounced hypointensity there. Diffusion-weighted imaging confirms marked restriction, mirrored by diminished ADC signal. Post-contrast dynamics show brisk, localized enhancement compared to adjacent tissue.
get_psa_trend
PSA trend shows a rise from 5.8 ng/mL (Jan 2023) to 3.7 ng/mL (Jan 2024) to 8.3 ng/mL (Jan 2025).
get_previous_notes
22 January 2024 - Dr. C. Peters (GP): Laboratory results today indicate a PSA concentration of 7.9 ng/mL, continuing an upward trajectory from the 6.2 ng/mL baseline documented in early 2023. A referral to the urology outpatient service has been processed for specialized evaluation and additional imaging.
get_lab_results
PSA: 8.3 ng/mL (29 Dec 2024, H). %Free PSA: 21% (29 Dec 2024). eGFR: <60 mL/min/1.73m2 (29 Dec 2024, L).

NOT RETRIEVED
The family-history anamnesis was not retrieved because it is not required for this decision based on the retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PI-RADS score: 5
- PSA velocity: 1.64 ng/mL/yr (based on trend data)
- Prior PSA: 7.9 ng/mL (from previous notes)
- Lesion size: 18 x 14 x 12 mm in the left peripheral zone (from MRI)

AGAINST sampling this patient now:
- Prior biopsy status: Positive (as noted in intake)
- csPCa predicted probability: 0.86351734 (which is high)

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high PI-RADS score, significant PSA velocity, and the context of a prior positive biopsy, which aligns with the guideline criterion that requires assessment of lesion change and surveillance status.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the evidence strongly suggests proceeding with biopsy due to the high PI-RADS score of 5 and the significant PSA velocity of 1.64 ng/mL/yr. The retrieved PSA trend, rising from 7.9 ng/mL to 8.3 ng/mL, combined with the high PI-RADS score, provides a strong indication that the lesion has changed sufficiently to warrant further tissue sampling to guide definitive management. The statistical prior suggested deferral, but the retrieved data points toward an informative next step.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
